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Atherosclerosis is the underlying condition in most cardiovascular diseases. Among the highly speciﬁc
cellular and molecular responses, endothelial dysfunction plays a key role in disease initiation and
progression. These events coincide with the occurrence of oxidative stress. Increased reactive oxygen
species production and oxidization of low-density lipoprotein are detected throughout atherosclerosis
progression. MicroRNAs (miRNAs) have emerged as important regulators of gene expression that
posttranscriptionally modify cellular responses and function. Accumulating studies indicate an inte-
grated miRNA network in the molecular mechanisms that control cellular homeostasis, vascular
inﬂammation, and metabolism. Experimental models of atherosclerosis highlight a direct link between
altered miRNA expression proﬁles and the pathophysiology of the disease and identify putative miRNA
candidates for the development of novel therapeutic strategies. In this review, we provide an overview of
the role of miRNA regulatory networks in oxidative stress in atherosclerosis and arterial remodeling and
discuss their potential therapeutic implications.
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MicroRNAs (miRNAs) have emerged as powerful regulators of
cardiovascular diseases. The majority of miRNA genes are initially
transcribed by RNA polymerase II as primary transcripts that
undergo maturation by sequential cleavage by the RNase III
endonucleases Drosha and Dicer. The mature miRNAs are small
noncoding molecules (20–25 nucleotides) that incorporate into the
RNA-induced silencing complex (RISC) and speciﬁcally guide it to
bind to target mRNA sequences usually in the 3′ untranslated
region (UTR) [1]. Multiple mechanisms of miRNA-mediated gene
repression have been described. Binding of the RISC to the target
mRNA can promote the degradation of the mRNA and/or inhibit its
translation, whereas binding of the miRNA complexes to the
promoter of target genes may induce epigenetic changes to the
chromatin and lead to transcriptional silencing [2,3]. MiRNA net-
works are particularly important under stress conditions to main-
tain homeostasis of biological systems. MiRNAs have numerous
targets often within the same functional pathway [4]. Their effects
on individual genes can be modest. However, miRNAs alter cellular
responses via a coordinated effect on multiple targets. In the
cardiovascular system, miRNAs have been shown to control key
aspects of development and pathophysiology [5]. Signature pat-
terns of miRNAs have been associated with distinct pathologies,
and miRNA-based therapeutic manipulations have been proposed
as promising strategies for cardiovascular diseases [6–8]. Here we
review the role of miRNAs in the pathogenesis of atherosclerosis
and the subsequent arterial remodeling and discuss their potential
therapeutic utility.Atherosclerosis and oxidative stress
In the vessel wall, endothelial cells (ECs), smooth muscle cells
(SMCs), and macrophages are sources of free radicals. A reduction
in nitric oxide (NO) bioavailability, attributed to a dysfunction of
the endothelial nitric oxide synthase (eNOS) enzyme and activity,
contributes to atherosclerosis [9]. Moreover, oxygen undergoes
univalent reduction by NADH/NAD(P)H and xanthine oxidase (XO)
to form superoxide. In the vasculature, superoxide is thought to being atheroprotective functions.
Cell type Target gene
ECs HOXA1
ECs Cyclin D1
Monocytes ORP9
ECs KLF2, VCAM
SMCs Sp1
SMCs KLF4, KLF5
Monocytes, macrophages IRAK1, TRA
Macrophages TLR4
Macrophages TNFα, IL-6,
ECs Importin-α
87, miR-125a, miR-99b, let-7e Monocytes, neutrophils NF-κB1
Monocytes LOX-1mainly derived from membrane-bound NAD(P)H oxidase and
mitochondria, whereas additional superoxide is generated by XO
catalyzing hypoxanthine and xanthine to uric acid [10]. In athero-
sclerosis, a profound imbalance of pro- and antioxidants causes
oxidative stress.
Despite the compelling evidence for a proatherogenic role of
oxidative stress, stimuli that are supposed to reduce oxidative
stress are not consistently associated with a reduction in athero-
sclerosis. For example, antioxidant treatments failed to offer
signiﬁcant protection in animal models and if an improvement
was observed, it was mainly attributed to increased NO bioavail-
ability or the induction of cytoprotective and anti-inﬂammatory
enzymes such as heme oxygenase 1 [11]. Oxidative processes such
as lipid oxidation, however, were largely unaffected. Thus, it is still
not entirely clear how oxidative stress accelerates atherosclerosis.MiRNAs in atherosclerosis and vascular remodeling
(Tables 1 and 2)
Accumulating evidence supports the notion that endothelial
homeostasis, innate and adaptive immunity, lipid metabolism, and
local blood ﬂow patterns are among the key regulatory processes
in atherogenesis [12–14].Endothelial cell activation
Endothelial dysfunction leads to increased endothelial perme-
ability, upregulation of endothelial adhesion molecules, and
inﬂammatory cell inﬁltration into the arterial wall. This cascade
of events ultimately results in atherosclerosis [15] and occurs at
preferred sites in the arterial tree that are associated with
disturbed laminar ﬂow, notably, arterial branch points and bifurca-
tions. Thus, hemodynamic forces inﬂuence the initiation of ather-
ogenesis [16]. The arterial endothelium, the interface between the
circulating blood and the vessel wall, is particularly susceptible. In
areas with complex patterns of blood ﬂow, ECs display a higher
turnover, decreased eNOS expression, and increased cytokine andFunction affected Ref.
Predisposition to vascular inﬂammation [21]
Proliferation of ECs [24]
Lipid uptake, cytokine expression [79]
-1 VEGF signaling. [22,26,27]
Proliferation of SMCs [55,56]
Proliferation of SMCs [47–53]
F6 Proinﬂammatory cytokine production [38–41]
Lipid accumulation, inﬂammatory response [80]
PYHIN, UBCH8, ZBP1 Cytokine production [42]
3 Inﬂammatory response [25]
Inﬂammatory response [43]
OxLDL internalization. [78]
Table 2
MiRNAs exhibiting proatherogenic functions.
MiRNA Cell type Target gene Function affected Ref.
MiR-21 ECs PPARα Derepression of AP-1, inﬂammatory response [19]
MiR-21 SMCs PTEN, Bcl-2, PDCD4 Proliferation of SMCs, senescence [57,59,63]
MiR-33a/b Macrophages ABCA1, ABCG1, NPC1, CROT, CPT1a, HADHB Lipid metabolism [64–70]
MiR-92a ECs KLF2, KLF4 Anti-inﬂammatory and vasodilatory properties of ECs [18,23]
MiR-122 Hepatocytes Lipid metabolism [72–75]
MiR-125b Macrophages IRF4 Inﬂammatory response of macrophages, responsiveness to IFN-γ [34,36]
MiR-144 Macrophages ABCA1 Cholesterol efﬂux [81,82]
MiR-146a SMCs KLF4 Proliferation of SMCs [61,62]
MiR-155 Macrophages IKKε, FADD, Ripk-1 Inﬂammatory response [34,35]
MiR-200c ECs ZEB1 Senescence [29,30]
MiR-217, miR-34a ECs Sirt1 Senescence [31,32]
MiR-221, miR-222 SMCs c-kit, p27, p57 Proliferation of SMCs, contractile gene transcription. [58,60]
MiR-342-5p Macrophages Akt1/miR-155 Inﬂammatory stimulation of macrophages [37]
MiR-633 ECs Induces a proinﬂammatory phenotype in ECs and monocyte adhesion [20]
MiR-758 Macrophages ABCA1 Cholesterol efﬂux [71]
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phenotype [17].MiRNAs associated with a proatherosclerotic EC phenotype
MiR-92a. MiR-92a seems to contribute to the endothelial
heterogeneity associated with atherosusceptible areas. In these
regions, endothelial miR-92a coregulates Krüppel-like-factors
2 and 4 (KLF2 and KLF4), critical regulators of endothelial
homeostasis. Two conserved sites of miR-92a were identiﬁed in
the KLF2 and KLF4 3′ UTR and reporter gene assays conﬁrmed that
miR-92a directly targets both transcription factors [18] and
modulates the anti-inﬂammatory and vasodilatory properties of
the endothelium.
MiR-21: MiR-21 is also upregulated by disturbed ﬂow and induces
a proinﬂammatory proﬁle of ECs through downregulation of
peroxisome proliferators-activated receptor-α (PPARα). As a result
derepression of activator protein 1 (AP-1) and enhanced adhesion
molecule and cytokine expression are observed [19].
MiR-633: Furthermore, a distinct miRNA signature is identiﬁed in
ECs exposed to oscillatory stress in vitro. MiR-633 displays the
most pronounced differences in expression and regulates the
disturbed ﬂow-induced proinﬂammatory phenotype of ECs and
monocyte adhesion to the endothelium [20].MiRNAs associated with protective EC phenotype.
MiR-10a: In response to mechanical forces in atherosusceptible
areas miR-10a is downregulated and the inﬂammatory response
directly modulated through the degradation of IκBα and nuclear
factor κB (NF-κB) signaling. HOXA1 is directly targeted by miR-10a
and mediates the expression of cytokines (MCP-1, IL-6, IL-8) and
adhesion molecules (VCAM-1, E-selectin). Thus, loss of endothelial
miR-10a expression is linked to the predisposition of vascular
inﬂammation in areas of disturbed ﬂow [21].
MiR-126: In contrast, areas of high laminar ﬂow are protected from
atherosclerosis. In these areas, ECs tend to align to the direction of
ﬂow, exhibit a quiescent phenotype, and express signiﬁcantly lower
inﬂammatory mediators [13]. The atheroprotective ﬂow induces the
expression of miR-126 that subsequently activates VEGF signaling,
through KLF2 upregulation [22]. Interestingly, downregulation of
miR-92a in response to high laminar ﬂow is an essential step for
the induction of KLF2 [23].MiR-19a: Suppression of EC proliferation by shear stress is, at least
in part, miRNA mediated. MiR-19a directly downregulates cyclin
D1 mRNA and protein expression in ECs exposed to laminar ﬂow
in a parallel plate ﬂow system. Inhibition of the endogenous
miR-19a attenuates the antiproliferative effect of ﬂow, suggesting
that miR-19a is important for endothelial homeostasis [24].
MiR-181b: Activation of ECs by proinﬂammatory stimuli that pro-
mote leukocyte recruitment is another trigger of vascular remodel-
ing. Cytokines such as tumor necrosis factor α (TNFα) alter the
miRNA proﬁle of ECs to orchestrate the upregulation of inﬂamma-
tory mediators. Nuclear translocation of the NF-κB dimer is an
essential step in the inﬂammatory process and largely depends on a
subset of importins—the α subgroup. Recent studies uncovered
a novel function of miR-181b in the endothelium that targets a
distinct member of importins, the importin-α3, and thus regulates
the NF-κB-mediated inﬂammation in the vessel wall. TNFα treat-
ment in ECs results in downregulation of miR-181b that facilitates
the induction of VCAM-1, ICAM-1, and E-selectin [25]. To add to the
complexity of the miRNA-mediated regulation, miR-126, miR-155,
miR-221, miR-222, miR-17-3p, and miR-31 also control the expres-
sion of VCAM-1 [26,27], ICAM-1, and E-selectin [28], suggesting a
highly coordinated manner of regulation of the inﬂammatory
response by the miRNA networks.
MiRNAs associated with vascular aging. Aging plays an important
part in the development and progression of atherosclerotic lesions.
EC senescence in particular has a profound effect on cell apoptosis
and disruption of the endothelial monolayer, rendering the
atherosclerotic plaque prone to rupture.
MiR-200c: In vitro, increased transcription of the miR-200c/141
cluster was observed in response to oxidative stress. Upregulation
of the mature miR-200c levels in ECs induced endothelial growth
arrest, apoptosis, and senescence, mainly owing to zinc-ﬁnger
enhancer binding 1 (ZEB1) transcription factor inhibition [29]. ZEB
transcription factors and miR-200 were previously shown to be
reciprocally linked in a feedback loop that tightly controls their
expression and regulates cell survival and senescence [30].MiR-217: MiR-217 also controls senescence. MiR-217 expression pro-
gressively increases with aging in endothelial cells. It is detected in
human atherosclerotic lesions and negatively correlated with Sirt1
[31]. Sirt1 is an NAD+-dependent class III histone deacetylase that is
upregulated under caloric restriction and has both antioxidant and
anti-inﬂammatory effects. Excessive reactive oxygen species (ROS) and
aging are known to decrease Sirt1 levels. Although the link between
A. Zampetaki et al. / Free Radical Biology and Medicine 64 (2013) 69–7772oxidative stress and miR-217 expression is yet to be established,
reporter assays indicated that miR-217 binds to the 3′ UTR and directly
regulates Sirt1 expression.
MiR-34a: In addition to miR-217, miR-34a was reported to target Sirt1
in ECs. High levels of miR-34a were observed in aging endothelium
that correlated with low levels of Sirt1. A miR-34a binding site in the
3′ UTR of Sirt1 and direct targeting were detected, although a
potential ROS-dependent regulation of miR-34a expression in EC
was not investigated [32].
Leukocyte inﬁltration: oxidative stress-responsive miRNAs
Adhesion of leukocytes to the inﬂamed endothelium is critical
for the development of atherosclerosis. NF-κB activation plays a
pivotal role in the inﬂammatory response.
After cleavage by Dicer, short double-stranded RNA duplexes
are generated from the miRNA precursors. Based on their stability
one of the strands is biologically active and represents the mature
miRNA, and the inactive strand, the so-called miRNA star strand
(miRNAn), is usually degraded. Oxidative stress seems to selec-
tively stabilize the miRNAn of speciﬁc miRNAs [4]. In macrophages,
a panel of oxidative stress-responsive miRNAs, namely miR-27an,
miR-27bn, miR-29bn, miR-24-2n, and miR-21n, was identiﬁed and
shown to modulate the NF-κB pathway, suggesting that macro-
phage functions may be affected [33].
MiR-155 and miR-125b
Proinﬂammatory stimuli result in differential miRNA expres-
sion in monocytes. MiR-155 and miR-125b show the most
pronounced changes after lipopolysaccharide (LPS), interferon-γ
(IFN-γ), or TNFα stimulation in an NF-κB-dependent manner and
have opposing effects on TNFα production [34]. Overexpression of
miR-125b induces an activated phenotype in macrophages and
elevates responsiveness to IFN-γ, whereas anti-miR-125b treat-
ment decreases CD80 surface expression, at least partially by
controlling IRF4 levels [35,36]. On the other hand, miR-155 results
in enhanced translation of TNFα, most probably by affecting the
stability of its transcript, and IKKε, FADD, and Ripk1—key media-
tors in the inﬂammatory response—were validated as direct
targets of miR-155. Increased TNFα expression that could render
them more susceptible to endotoxin shock was observed in mice
overexpressing miR-155 in B cells, indicating that miR-155 exerts
both positive and negative effects on LPS signaling. A cross talk
between miR-342-5p and miR-155 was recently reported to affect
the inﬂammatory activation of macrophages in atherosclerotic
lesions. Increased expression of miR-342-5p macrophages in early
atherosclerotic lesions suppressed the expression of Akt1 and led
to upregulation of miR-155 and increased nitro-oxidative stress
[37].
MiR-146a/b
The expression of miR-146a/b in monocytes is strongly affected
by proinﬂammatory stimuli such as LPS through an NF-κB-
dependent mechanism. The adaptor molecules IRAK1 and TRAF6
are bona ﬁde miR-146a targets, suggesting a novel mechanism of
negative-feedback regulation of Toll-like receptor (TLR) and NF-κB
activation [38,39]. Of note, the expression of miR-146a in periph-
eral blood mononuclear cells is signiﬁcantly increased in patients
with acute coronary syndrome [40]. Targeted deletion of miR-146a
in mice leads to hyperresponsiveness to LPS and excessive produc-
tion of proinﬂammatory cytokines (TNFα, IL-6). Stimulation of
miR-146a-deﬁcient macrophages with LPS results in an overpro-
duction of TNFα and IL-6 proteins. In contrast, monocytes with
ectopic expression of miR-146a display a diminished inﬂammatoryresponse [41]. In addition to acting as a molecular brake on
inﬂammation, miR-146a also controls immune cell proliferation
as the miR-146a-null mice develop a spontaneous autoimmune
disorder and die prematurely.
MiR-147
In a similar manner, miR-147 displays potent anti-inﬂammatory
properties and attenuates the expression of proinﬂammatory cyto-
kines in macrophages stimulated with TLR2, TLR3, and TLR4
ligands, whereas its expression is dependent on NF-κB and IRF3
signaling. Transfection of miR-147 mimics into peritoneal macro-
phages signiﬁcantly decreases LPS-induced TNFα and IL-6 produc-
tion as well as the expression of several other LPS-induced genes,
such as PYHIN, UBCH8, and ZBP1, and importantly the expression
level of miR-147 as well. Overall, miR-147 has emerged as part of a
negative-feedback loop that can inhibit the proinﬂammatory
response of macrophages and prevent excessive inﬂammation [42].
Other miRNAs
Additional miRNAs (miR-9, miR-187, miR-125a, miR-99b, and
let-7e) are induced by LPS in human monocytes and neutrophils.
Upregulation of miR-9 is consistently observed in monocytes after
activation with LPS, TNFα, and IL-1β but not IFN-γ. A conserved
miR-9 binding site on the NF-κB1 transcript and a miR-9-
dependent inhibition were identiﬁed. Thus, miR-9 was proposed
to be part of an inhibitory feedback loop in the inﬂammatory
response, acting at the level of NF-κB1 [43].
Inﬁltration of monocytes in the lesion sites is fundamental for
the development of atherosclerosis. Distinct monocyte subsets
have been implicated in the pathogenesis of the disease. The
potential correlation between miRNA signatures in monocytic
subsets and atherosclerotic plaque has been investigated and
miR-99b, miR-152, and miR-422a expression was reported in
monocytes and atherosclerotic plaques, but not in healthy vessels.
This ﬁnding may imply monocyte accumulation in the vessel wall
and novel candidate miRNAs that could serve as targets for
therapeutic interventions [44].
Smooth muscle cell proliferation and migration
Neointima formation is a common feature of vessel remodeling.
In response to endothelial dysfunction and inﬂammatory cell
inﬁltration, SMCs migrate from the media to the intima and
proliferate to form neointimal lesions. The switch from a contrac-
tile to a synthetic proliferative phenotype in SMCs is controlled by
miRNAs.
MiR-143/145
The miR-143/145 cluster is a cardiac and smooth muscle cell-
speciﬁc cluster [45] and its expression is directly regulated by
serum response factor (SRF) and Nkx2.5 and the Jag-1/Notch
pathway [46]. Several lines of evidence suggest that this cluster
is essential for the acquisition of the contractile phenotype, SMC
differentiation, and the structural integrity of the aorta. SMCs from
miR-143/145-null mice maintain a proliferative state that favors
neointima formation [47]. The mutant mice developed neointimal
lesions in the absence of hyperlipidemia, lipid depositions, and
foam cells. Angiotensin-converting enzyme was identiﬁed as a
direct target of this miRNA cluster and its inhibition could partially
rescue the phenotype in miR-143/145-null mice. Further support
to this notion was provided by studies in rats using a model of
carotid artery balloon injury. A critical role of miR-145 was
demonstrated in SMC phenotype and neointima formation. KLF5
emerged as the direct target of miR-145 that mediated the
observed phenotypic modulation [48]. Additionally, transforming
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phenotype of SMCs in vitro through an upregulation of miR-143/
145 that targeted KLF4 expression [49,50]. Maintaining the differ-
entiated state of SMCs is critical in various pathologies such as
atherosclerosis, restenosis, and aneurysm, and downregulation of
miR-143/145 is a common feature. Likewise, structural modiﬁca-
tions of the aorta due to incomplete differentiation were reported
in miR-143/145-null mice [51]. Moreover, these mice display
signiﬁcant reduction in blood pressure probably due to diminished
vascular rigidity, whereas in response to vascular injury they have
impaired neointimal formation and reduced migratory activity of
SMCs. Modulation of cytoskeletal assembly is considered to con-
tribute to this phenotype, as miR-143/145 [52] were shown to
affect the release of the myocardin-related transcription factors
from actin, their nuclear translocation, and their interaction with
SRF [53].
MiR-133
MiR-133, a miRNA highly abundant in skeletal and cardiac
muscle [54] but also detectable in the aorta, was recently reported
to prevent the phenotypic switching of SMCs in vitro and in vivo.
Gain- and loss-of-function experiments revealed that miR-133
directly regulates the transcription factor Sp-1 and its downstream
target KLF4 [55]. Thus, miR-133 decreases SMC proliferation
in vitro and in vivo and its expression is markedly reduced after
balloon injury in the carotid artery. Likewise, expression levels of miR-
133 were correlated with plaque stability in humans. Comparison of
the miRNA proﬁle of symptomatic and asymptomatic atherosclerotic
plaques revealed a signiﬁcant upregulation of miR-133 in symptomatic
plaques [56].
Other miRNAs
Unlike miR-133, miR-21, miR-221, and miR-222 promote SMC
survival, proliferation, and dedifferentiation. Identiﬁed as differ-
entially expressed and localized in SMCs in neointimal lesions
these miRNAs have distinct functions: miR-21 by modulating
apoptosis via regulation of PTEN and Bcl-2; miR-221 and miR-222
by controlling proliferation via targeting p27 (Kip1) and p57 (Kip2)
[57–59]. The pleiotropic effects of platelet-derived growth factor
(PDGF) seem to be mediated at least in part by miR-221. Induced by
PDGF-BB treatment in SMCs, this miRNA speciﬁcally targets c-kit
and p27/Kip1 and inhibits SMC-speciﬁc contractile gene transcrip-
tion [60]. In a similar manner, miR-146a—a miRNA that is upregu-
lated in human atherosclerotic plaques—was shown to promote
SMC proliferation and neointimal hyperplasia through a feedback
loop with KLF4 [61,62]. As far as oxidative stress and SMC apoptosis
are concerned, an unexpected role for ROS-mediated upregulation
of miR-21 was uncovered. Programmed cell death 4 was identiﬁed
as a direct target of miR-21. Interestingly, upregulation of miR-21
expression inhibited ROS-mediated SMC apoptosis and death and
had an antiapoptotic albeit modest effect [63].
MiRNA-mediated lipid metabolism and atherosclerosis
The link between hypercholesterolemia and atherosclerosis is
well established. The role of miRNAs in regulating lipid metabo-
lism has only been discovered recently.
MiR-33a/b
Two intronic miRNAs, miR-33a and miR-33b, have been identi-
ﬁed as critical regulators of lipid metabolism. Encoded within the
sterol response element binding protein genes (SREBP2 and
SREBP1), they represent a feedback loop that ﬁne-tunes fatty acid
and cholesterol levels [64,65]. Their targets include genes involved
in cholesterol export and high-density lipoprotein (HDL) synthesis(ABCA1, ABCG1, and NPC1) and fatty acid oxidation (CROT, CPT1a,
HADHB) [66,67]. Antagonism of miR-33 in low-density lipoprotein
(LDL) receptor-null mice gave promising results for the treatment
of atherosclerosis. These mice show increased levels of circulating
HDL, enhanced reverse cholesterol transport, and regression of
established atherosclerotic plaques [68,69]. In nonhuman pri-
mates, systemic administration of anti-miR-33 induced hepatic
expression of ABCA1 and resulted in a sustained increase in
plasma HDL [70].
MiR-758
ABCA1 is a critical transporter in cholesterol efﬂux and thus its
regulation was further interrogated using bioinformatic analysis.
It was shown that its 3′ UTR may also be targeted by miR-758,
a miRNA that is repressed in cholesterol-loaded macrophages.
Experimental evidence conﬁrmed that miR-758 posttranscription-
ally regulates ABCA1 expression in macrophages, hepatocytes, and
astrocytes and has a signiﬁcant impact on cholesterol efﬂux [71].
MiR-122
Remarkable effects on plasma cholesterol levels were obtained
by manipulating miR-122 expression as well. MiR-122 is one of the
most abundant miRNAs in the liver and regulates lipid metabolism
[72]. Targeting miR-122 in mice resulted in a sustained decrease in
plasma cholesterol, in both HDL and LDL fractions [73,74]. These
ﬁndings were extended to nonhuman primates, in which antag-
onism of miR-122 in African green monkeys led to signiﬁcantly
lower cholesterol in the circulation without apparent toxicity [75].
Let-7g
After increased endothelial permeability, the exacerbated ROS
production by activated macrophages leads to lipoprotein oxida-
tion (oxLDL) and deposition of modiﬁed lipoproteins in the arterial
wall, a key event in the progression of the disease [76]. OxLDL can
further activate ECs that adapt a proinﬂammatory phenotype,
leading to leukocyte recruitment. As oxLDL and other lipid-
loaded monocytes accumulate they are transformed into foam
cells that form the fatty streaks in the intima [77]. The scavenger
receptor lectin-like oxidized low density receptor-1 (LOX-1) med-
iates the binding and internalization of oxLDL into cells and plays
an active role in atherosclerosis by stimulating a proinﬂammatory
phenotype. A negative feedback regulation between let-7g and
LOX-1 that affects proliferation and cell migration was recently
reported. Serum levels of let-7g were signiﬁcantly reduced in
subjects with hypercholesterolemia compared to controls [78].
MiR-125-5p/miR-146a
In circulating cells, stimulation with oxLDL resulted in a distinct
miRNA proﬁle and a marked upregulation of miR-125a-5p and
miR-146a. In human peripheral blood monocytes manipulation of
miR-125a-5p levels led to changes in lipid uptake and the secre-
tion of cytokines. Although the molecular mechanisms involved
are still not clear it was proposed that the oxysterol-binding
protein-like 9, with its diverse functions in lipid metabolism, is
directly targeted by miR-125a-5p [79]. MiR-146a, on the other
hand, inhibits oxLDL-mediated lipid accumulation and inﬂammation
in macrophages through direct targeting of TLR4 [80].
MiR-144
Two independent groups simultaneously identiﬁed the role of
miR-144 in cholesterol metabolism, via suppression of ABCA1.
A novel pathway that involves activation of the liver X nuclear
receptors or the bile acid receptor farnesoid X receptor increased
expression of miR-144, and downregulation of ABCA1 was shown to
regulate plasma HDL cholesterol [81,82]. In mice, overexpression of
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and HDL biogenesis in the liver.
Secreted miRNAs and atheroprotection
A novel concept of intercellular communication via secreted
vesicles has been recently reported. Several lines of evidence
suggest that various stimuli induce the release of vesicles that
carry distinct miRNA signatures, implying active packaging of
these carriers that could facilitate speciﬁc functions. The speciﬁcity
of cellular secretion of miRNAs was reported in monocytes after
stimulation with LPS, H2O2, or oleic acid/palmitic acid and treat-
ment with advanced glycation end products. Remarkably, more
pronounced differences were observed in the secreted than in the
cellular miRNA pool [83]. In a pioneering study using next-
generation sequencing Diehl et al. [84] reported a distinct miRNA
pattern of expression in microparticles derived from stimulated or
unstimulated monocytes or endothelial cells compared to the
miRNA cellular pool. These ﬁndings provided further support to
the notion that microparticles may act as transport vehicles
delivering speciﬁc miRNAs. Cellular export to protein and
lipoprotein complexes has also been described. Argonaute (Ago)–
miRNA complexes were detected in the circulation and their
miRNA proﬁle was reliably characterized [85], indicating that
functional miRNA-induced silencing complexes are released from
the cells. In lipoproteins, a speciﬁc miRNA pool was detected. The
miRNA content identiﬁed in HDL complexes from atherosclerotic
individuals was shown to induce differential gene expression in
hepatocytes, indicating that HDL may participate in a miRNA-
mediated mechanism of intercellular communication [86],
although it is still not clear if this is a common or rather
specialized mechanism [87].
MiR-126
MiR-126, residing in endothelial cell-derived apoptotic bodies,
was shown to induce the degradation of RGS16, induce CXCR4
signaling, and enhance CXCL12, which can mobilize progenitor
cells. This was proposed to promote CXCR4-dependent mobiliza-
tion and recruitment of stem cell antigen-1-positive progenitor
cells to atherosclerotic plaques in mice and has led to a decrease in
diet-induced atherosclerosis as well as collar-induced plaque
formation [88]. Packaging of miR-126 in microvesicles seems to
be tightly regulated. A signiﬁcant reduction in the miR-126
content of endothelial particles released under hyperglycemic
conditions was detected in vitro in ECs. This regulatory mechanism
was further conﬁrmed in a population study. In diabetic indivi-
duals, reduced miR-126 expression was detected in circulating
particles compared to healthy controls [6]. In addition to endothe-
lial particles, in an intervention study in humans, a positive
correlation between miR-126 and platelet microparticles was
observed on day 2 after ischemia/reperfusion injury, suggesting
that miR-126 is responsive to the vascular stimulation [8]. An
intriguing role for the endothelial secreted miR-126 in SMC turn-
over was recently revealed in low shear stress. MiR-126 emerged
as a paracrine mediator that can shift gene expression and
function in SMCs toward a proatherogenic phenotype [89].
MiR-150
A miRNA-mediated cross talk between monocytes and
endothelial cells in atherosclerosis has also been demonstrated.
MiR-150 secreted from monocytic cells was shown to enhance
endothelial cell migration. Monocytic cells secrete miR-150 and its
levels in microvesicles increase in response to inﬂammatory
stimuli. Circulating microvesicles from patients with atherosclero-
sis contain increased levels of miR-150. Treatment of endothelialcells with these vesicles resulted in enhanced migration. A direct
target of miR-150, the transcription factor c-Myb, was found to
mediate this response [83]. c-Myb controls cell proliferation,
lineage commitment, and migration.
MiR-143/145
EC and SMC cross talk is also important to maintain SMCs in a
contractile and atheroresistant state. A recent study suggests that
ECs communicate with SMCs through vesicles that transfer miR-
143/145 and confer atheroprotection. The concept that secreted
miRNAs can induce a phenotype switch in SMCs is intriguing, as
miR-143/145 concentrations are already high in cultured SMCs,
even in the absence of ECs. It is currently unclear how ECs could
deliver sufﬁcient amounts of miR-143/miR145 [90] to prevent an
SMC switch to a synthetic, proliferative, and proatherogenic
phenotype. In principle, exosomes and other vesicles may act as
carriers of genetic information in the form of miRNAs and could be
exploited for the development of novel therapeutic approaches.
However, the exact mechanism of targeted cellular uptake is still
unknown.Circulating miRNAs
Blood cells are probably the most important contributors to
circulating miRNAs. Consequently, changes in blood cell counts
and hemolysis will have a signiﬁcant inﬂuence on circulating
miRNA levels. Moreover, a larger proportion of plasma microve-
sicles are derived from platelets with only a smaller percentage
coming from endothelial cells. As shown in interventional studies
in healthy volunteers, ischemia/reperfusion injury results in a rise
of miRNAs that are abundant in platelets and platelet microparti-
cles, such as miR-223, -126, -24, -21, and -197. In contrast,
antiplatelet therapy is associated with decreased shedding of
platelet microparticles and a corresponding reduction of platelet
miRNAs in plasma [91]. Nonetheless, comparisons of Ago1- and
Ago2-associated miRNAs in plasma and full blood have revealed
signiﬁcant differences in the miRNA proﬁles [92], indicating that
some circulating miRNAs originate from other organs, i.e., liver
(miR-122), muscle (miR-133a), or heart (miR-208a). Heart-speciﬁc
miRNAs are released after myocardial infarction and implicated as
potential biomarkers similar to troponins [93,94]. Effects of
heparin, however, have to be taken into account when designing
studies to investigate the relation of circulating microRNAs to
acute cardiovascular events or coronary intervention [95,96].MiRNA therapeutics
MiRNAs have unique functions and are promising candidates
for novel therapeutic interventions. They have a small size and
highly conserved sequence and miRNA networks exert a mild
effect at baseline but pronounced biological functions under stress.
Their ability to target pathways instead of individual effectors and
thus overcome potential redundancy mechanisms is a particularly
useful feature in designing novel miRNA-based therapeutic stra-
tegies [97]. On the other hand given the multiplicity of miRNA
targets it would be hard to avoid “off-target” effects. In addition,
only a few of the studied miRNAs are tissue speciﬁc and hence
targeting speciﬁc organs may be particularly challenging [98].
A variety of chemistries for miRNA inhibitors have been developed
and the efﬁcacy, speciﬁcity, and toxicity of these constructs are
being tested extensively in animal models [99,100]. There are
several issues that need to be addressed regarding their cellular
uptake, storage, and mode of action, whereas data from large
animal studies are required before therapeutic inhibition of
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Even so, miRNA therapeutics is a fast-evolving ﬁeld that could
offer opportunities for novel therapeutic approaches.Conclusions
Although increased ROS production has been observed in
cardiovascular diseases, attenuation of oxidative stress has so far
not translated into a successful therapeutic intervention. In the
vascular setting, additional studies are required to further char-
acterize the function and regulation of miRNAs responsive to
oxidative stress. Nevertheless, substantial progress has been made
in understanding the role of miRNAs in targeting the various
aspects of atherogenesis and arterial remodeling. The concept has
emerged that miRNAs take part in positive as well as negative
regulatory loops and may function as networks rather than
individual regulators. Identifying the critical miRNAs that govern
the processes of response to vascular injury and resolution of
inﬂammation is a formidable task. It requires an understanding of
the temporal and spatial relationship of miRNA expression in the
various cell types that interact in the vessel wall. If miRNA mimics/
inhibitors could be delivered effectively in a targeted rather than a
systemic manner, miRNA therapeutics may represent novel oppor-
tunities to halt the development of atherosclerosis.Acknowledgments
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